Ptc Therapeutics (PTCT) Accounts Payables (2012 - 2026)

Ptc Therapeutics' Accounts Payables history runs 15 years deep, the most recent figure standing at $313.0 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 1966.34% year-over-year to $313.0 million; the TTM figure through Mar 2026 stood at $313.0 million (up 1966.34% YoY), while the FY2025 annual figure was $381.3 million, up 25.3% from the prior year.
• Accounts Payables was $313.0 million for Q1 2026 at Ptc Therapeutics, down from $381.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $392.0 million in Q4 2023 to a low of $15.2 million in Q1 2025.
• Historically, Accounts Payables has averaged $172.1 million across 5 years, with a median of $36.6 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Accounts Payables plunged 95.42% in 2025, then jumped 1966.34% in 2026.
• A 5-year view of Accounts Payables shows it stood at $320.4 million in 2022, then grew by 22.35% to $392.0 million in 2023, then fell by 22.37% to $304.3 million in 2024, then advanced by 25.3% to $381.3 million in 2025, then decreased by 17.89% to $313.0 million in 2026.
• The last three Accounts Payables figures came in at $313.0 million (Q1 2026), $381.3 million (Q4 2025), and $36.6 million (Q3 2025), per Business Quant data.